[go: up one dir, main page]

AR123227A1 - Terapias combinadas para su uso en el tratamiento del cáncer - Google Patents

Terapias combinadas para su uso en el tratamiento del cáncer

Info

Publication number
AR123227A1
AR123227A1 ARP210102262A ARP210102262A AR123227A1 AR 123227 A1 AR123227 A1 AR 123227A1 AR P210102262 A ARP210102262 A AR P210102262A AR P210102262 A ARP210102262 A AR P210102262A AR 123227 A1 AR123227 A1 AR 123227A1
Authority
AR
Argentina
Prior art keywords
treatment
cancer
combination therapies
combination
agents
Prior art date
Application number
ARP210102262A
Other languages
English (en)
Inventor
Marc Lee Hyer
Petar Kalev
Katya Marjon
Kevin Marks
Fu Li
Original Assignee
Servier Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Pharmaceuticals Llc filed Critical Servier Pharmaceuticals Llc
Publication of AR123227A1 publication Critical patent/AR123227A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El compuesto de la fórmula (1), o sus sales farmacéuticamente aceptables, es útil, entre otras cosas, en el tratamiento del cáncer y proporciona una ventaja terapéutica cuando se usa en combinación con otros agentes como se describe en la presente en comparación con el tratamiento con cada agente cuando se administra solo.
ARP210102262A 2020-08-12 2021-08-12 Terapias combinadas para su uso en el tratamiento del cáncer AR123227A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063064786P 2020-08-12 2020-08-12

Publications (1)

Publication Number Publication Date
AR123227A1 true AR123227A1 (es) 2022-11-09

Family

ID=80247372

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102262A AR123227A1 (es) 2020-08-12 2021-08-12 Terapias combinadas para su uso en el tratamiento del cáncer

Country Status (3)

Country Link
AR (1) AR123227A1 (es)
TW (1) TW202227082A (es)
WO (1) WO2022036067A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54452A (fr) 2018-12-10 2022-03-16 Ideaya Biosciences Inc Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
WO2023201338A1 (en) * 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
CN117487914B (zh) * 2023-10-27 2025-01-03 广东药科大学 靶向zc3h18/pd-l1信号轴在肿瘤免疫逃逸检测、治疗、预后中的应用
WO2025157286A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和mat2a抑制剂的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ758548A (en) * 2013-11-11 2022-02-25 Amgen Inc Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2016145150A2 (en) * 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
EP3377068B1 (en) * 2015-11-20 2025-03-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
AU2016364855B2 (en) * 2015-12-03 2019-08-29 Les Laboratoires Servier MAT2A inhibitors for treating MTAP null cancer
UA125852C2 (uk) * 2016-08-31 2022-06-22 Ле Лаборатуар Сервьє Інгібітори клітинних метаболічних процесів

Also Published As

Publication number Publication date
WO2022036067A4 (en) 2022-04-07
TW202227082A (zh) 2022-07-16
WO2022036067A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
AR123227A1 (es) Terapias combinadas para su uso en el tratamiento del cáncer
MX2022000143A (es) Metodos novedosos.
MX2020013607A (es) Sistemas y métodos para acceder a senos.
JP2016155880A5 (es)
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
MX2025004156A (es) Composiciones topicas para el alivio del dolor.
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
MX391719B (es) Agentes de quimioembolizacion.
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
MX2020010417A (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
MX2021005876A (es) Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama.
AR087803A1 (es) N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla
CL2021002146A1 (es) Tratamientos combinados para su uso en el tratamiento del cáncer.
AR125331A1 (es) Combinación que comprende ribociclib y amcenestrant
ECSP077843A (es) Tratamiento o prevención del prurito
MX2024003563A (es) Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa.
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.

Legal Events

Date Code Title Description
FB Suspension of granting procedure